Back to results
US 2023/0146944 A1Published application
Heterocyclic compounds and their use for treatment of helminthic infections and diseases
AssigneesCelgene Corporation, Zoetis LLC
InventorsNatalie Hawryluk, Stacie S. Canan, Kevin R. Condroski, Graham Kyne, Matthew Bedore, Sanjay Menon
Life of this patent
Estimating the term…
Abstract
Provided herein are Heterocyclic compounds of formula I: and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.
Claims48
A compound of Formula (I)
- or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof,
- wherein:
- W is N or NR;
- X is N, NR, O, or S;
- Y is N, NR, O, or S;
- R1 is 2-pyridyl, 3-pyridyl, pyrazinyl, or pyrimidyl, each unsubstituted or substituted with one or more substituents independently selected from halogen, CN, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted 3-6 membered heterocyclyl, —NR2, —COOR, —OR3, —SO2NR2, —SO2 (substituted or unsubstituted heterocyclyl), —N(R)CO(R4), —CON(R5)2, and substituted or unsubstituted C6-10 aryl;
- R2 is
- each unsubstituted or substituted with one or more substituents Z, wherein Z is independently selected from halogen, CN, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted 3-6 membered heterocyclyl, —NR(substituted or unsubstituted C3-7 cycloalkyl), —N(R)COR, —COOR, —SO2(C1-3 alkyl), —SO2NR2, —SO2 (substituted or unsubstituted heterocyclyl), —OR6, and —CON(R7)2;
- or two Z together with the carbons to which they are attached form a substituted or unsubstituted 5-6 membered heterocyclyl or substituted or unsubstituted C5-6 heteroaryl;
- Each R3 is independently selected from substituted or unsubstituted C1-5 alkyl, or substituted or unsubstituted 3-6 membered heterocyclyl;
- Each R4 is independently selected from substituted or unsubstituted C1-5 alkyl, or substituted or unsubstituted C3-6 cycloalkyl;
- Each R5 is independently selected from H, substituted or unsubstituted C1-5 alkyl, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted (C1-3 alkyl)(C3-6 cycloalkyl), or two R5 and the nitrogen to which they are attached form a substituted or unsubstituted 3 to 6 membered heterocyclyl;
- Each R6 is independently selected from substituted or unsubstituted C1-5 alkyl, substituted or unsubstituted C3-6 cycloalkyl, —(C1-3 alkyl)(substituted or unsubstituted C3-6 cycloalkyl), or substituted or unsubstituted 3-8 membered heterocyclyl;
- Each R7 is independently selected from H, and substituted or unsubstituted C1-5 alkyl, or two R7 and the nitrogen to which they are attached form a substituted or unsubstituted 3 to 6 membered heterocyclyl;
- RN is H, or substituted or unsubstituted C1-5 alkyl;
- and
- each R is independently selected from H and substituted or unsubstituted C1-4 alkyl;
- provided R1 and R2 are not both unsubstituted.
15 more elements
(canceled)
(canceled)
36-54. (canceled)
Dependencies are inferred from the claim text.